Submission Deadline
05 Jul 2022 (Vol 45 , Iss 05 )

Upcoming Publication
31 Jul 2022 (Vol 45 , Iss 05 )

Journal ID : TMJ-19-03-2022-11205
Download [This article belongs to Volume - 45, Issue - 02]
Total View : 368

Title : Effect of non-calcium based phosphate binders versus calcium based binders on Chronic Kidney Disease- Mineral and Bone disorder in children undergoing hemodialysis: An Egyptian study

Abstract :

Chronic kidney disease (CKD) is frequently accompanied by hyperphosphatemia. High serum phosphate usually requires dietary measures, adequate dialysis prescription and/or phosphate binders. Hyperphosphatemia in CKD is assumed to lead to cardiovascular and bone complications. The current study aimed to compare between sevelamer hydrochloride and calcium-based phosphate binders (CPB) in management of hyperphosphatemia in children with end stage renal disease (ESRD) on regular hemodialysis (HD). A randomized controlled trial was conducted over one year duration. Forty patients with ESRD on HD were enrolled and randomly subdivided into two groups either received Sevelamer hydrochloride (group A) or CPB (group B). Those patients were followed with laboratory data and echocardiography. Both groups had no significant differences as regard baseline data, laboratory data and echocardiography but group B had significantly higher serum calcium and calcium x phosphorus ratio. It was found that parathyroid hormone, systolic blood pressure, phosphorus level, calcium level, duration of dialysis, hemoglobin level, body surface area and age associated with presence of left ventricular hypertrophy. Sevelamer HCL is more effective in management of hyperphosphatemia in ERSD but still the main limitation of its use is the high cost.

Full article
//